PD-L2 Nuclear Localization for Therapy Response Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to accurately predict patient response to therapies due to the complex role of PD-L2 localization in immune cells, leading to ineffective treatments and disease progression.
Innovation Solution
Analyzing the cellular distribution of PD-L2, particularly its nuclear localization, to determine the likelihood of patient response to therapies such as anti-infective, cytotoxic, or immunotherapy, using methods that detect the presence, level, or co-localization of PD-L2 with nuclear binding partners like histone polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing methods are used to predict patient response to therapy, then treatment decisions can be made, but prediction accuracy is insufficient leading to ineffective treatments
Solution Approach 1:
The invention changes the parameter being measured from general PD-L2 expression levels to specific nuclear localization of PD-L2. This parameter change enables more accurate prediction of patient response to therapy by detecting the presence or absence of PD-L2 in the nucleus, which correlates with resistance or sensitivity to treatment, thereby improving both measurement precision and treatment reliability
Solution Approach 2:
The invention introduces nuclear binding partners of PD-L2 (such as histone polypeptides) as intermediary markers. By detecting the co-localization of PD-L2 with these nuclear binding partners, the method provides an indirect but accurate way to assess nuclear PD-L2 presence, improving prediction accuracy without requiring direct measurement of PD-L2 function
2Ease of operation
If PD-L2 expression is analyzed without considering localization, then analysis is simplified, but prediction of therapy response is inaccurate
Solution Approach 1:
The invention segments the cellular analysis into distinct compartments by specifically targeting nuclear localization of PD-L2. Instead of analyzing the entire cell, the method focuses on detecting PD-L2 within the nucleus using nuclear binding partners as markers. This segmentation maintains analytical simplicity while dramatically improving prediction accuracy by concentrating on the functionally relevant compartment
3Adaptability or versatility
If general immune status markers are used, then broad immune function can be assessed, but specific prediction of therapy resistance or sensitivity is not achieved
Solution Approach 1:
The invention applies the local quality principle by focusing on a specific location (nucleus) and specific interaction (PD-L2 with nuclear binding partners) rather than measuring general immune markers throughout the cell. This localized approach provides precise prediction of therapy response while maintaining the ability to assess immune status, as nuclear PD-L2 localization specifically indicates resistance mechanisms
Data Source
AI summary
Disclosed are methods and agents for predicting response to therapy, immune status and/or disease progression. More particularly, disclosed are methods, agents and kits for analyzing cellular distribution of PD-L2, including its nuclear localization, for stratifying a patient as a likely responder or non-responder to a therapy, for managing treatment of a patient with a therapy, for monitoring a disease in a patient following treatment with a therapy, for determining the status of a disease and/or for determining the immune status of a patient.